Adam Zamecnik

Adam Zamecnik

Reporter

London, UK

Adam has previously worked at GlobalData Media as a Healthcare Reporter, writing longer and shorter articles for the public website Pharmaceutical Technology and the Pharma Intelligence Centre. During his time there, Adam focused on topics such as cell and gene therapy, vaccine research, and new approaches to the treatment of haematological conditions. He has also covered the development of new biosimilars, the production of complex generics, and legal battles between Big Pharma. Prior to this, Adam wrote as a freelance reporter for the likes of Vice World News. Adam holds an MA in International Journalism from City, University of London.

Latest from Adam Zamecnik

Brazil’s Hypera Unanimously Rejects EMS’ Proposed Merger

Only days after its initial announcement, Hypera Pharma has refused EMS’ proposed merger on grounds of undervaluation and different strategic priorities.

PharmaTher’s Ketamine Formulation Receives CRL From FDA

After sharing multiple updates to the regulatory status of its ketamine formulation, PharmaTher received a complete response letter from the FDA, which required minor information and clarifications from the company.

Alvotech And Fuji File Third Biosimilar Application In Japan

Only a month after filing their second biosimilar application with Japanese regulators, Alvotech and Fuji have submitted a further one for an undisclosed biosimilar as part of their local partnership.

Indian Patent Office Dismisses ViiV’s Controversial HIV Drug Claims

Years after the patent application’s initial filing in 2007, the Indian Patent Office has dismissed ViiV’s claims in response to multiple opposition filings launched against the pharma player.

Government And Industry Stakeholders Debate Future Of European Drug Supply

Delegates from European institutions and industry representatives unpacked the many challenges of improved access to critical medicines on the continent in a session at this year’s European Health Forum.

ViiV Commits To Tripling Apretude PrEP Supply In Low Income States

Days after Gilead’s signing of voluntary licensing with six generic manufacturers for its HIV drug Sunleca, ViiV announced its commitment to ramping up Apretude’s supply to countries in need.